– UK, Oxford – Oxford Biomedica plc (LON: OXB), a leading gene and cell therapy group, today announced the appointment of Namrata Patel to its Board as an Independent Non-Executive Director with immediate effect.
“Namrata is a high calibre and timely appointment for Oxford Biomedica as we advance our manufacturing and CMC capabilities, whilst expanding our global presence. We warmly welcome her to the Board and look forward to utilising her international manufacturing and supply chain expertise, as well as her experience in sustainability as we deliver on our aim of becoming a global fully integrated viral vector leader.” said Chair and Interim CEO, Dr. Roch Doliveux.
About Namrata P Patel
Namrata Patel has extensive international experience in manufacturing and end-to-end Supply Chain with experience in the commercialized regulated industry. She is currently SVP, Product Supply, within the Global Beauty Sector at Procter & Gamble (NYSE: PG), a US-listed, multi-national consumer goods business, having joined the company 25 years ago. Ms. Patel has held senior positions across several major global markets and plays a key role in delivering on Procter & Gamble’s 2040 Sustainability Ambition Goals for its Beauty Business portfolio.
Over the course of her career, Ms. Patel has worked at several major multi-national corporations, holding senior positions at Gillette, WH Smith, and Coca-Cola, with a strong focus on international supply chain management. She holds a master’s in Logistics and Management from the Cranfield School of Management, and a BA in Public Administration & Marketing from the University of South Wales, Mid Glamorgan.
Ms. Namrata Patel said: “Oxford Biomedica is at an exciting time in its development as it broadens its scope into AAV and significantly expands its manufacturing capacity to meet the growing global demand for its viral vector capabilities. I look forward to working closely with the rest of the Board and the management team as the Company continues to progress as a global leader in the gene and cell therapy space.”
About Oxford Biomedica
Oxford Biomedica is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries have built a sector-leading lentiviral vector delivery platform, which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders, and liver diseases. The Group has also entered into several partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics, and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral-based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK, and employs more than 740 people.
For more information: https://www.oxb.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
